Idorsia effectively started its operation after demerging from Actelion on 15 June 2017, and registered shares of Idorsia Ltd were listed on the SIX Swiss Stock Exchange on the next day. As of this date, Idorsia was fully operational with over 600 employees, a rich clinical development pipeline of ten assets, equipped with state-of-the-art facilities and funded with CHF 1 billion.


For the period ending 30 September, the US GAAP operating loss amounted to CHF 79 million, including a non-GAAP operating loss of CHF 71 million, driven by R&D expenses of CHF 57 million and G&A expenses of CHF 14 million, depreciation and amortization of CHF 5 million and share-based compensation of CHF 3 million.

The US GAAP net loss amounted to CHF 82 million resulting in a net loss per share of CHF 0.73.

 

 Idorsia's key numbers

Period ended September 30, 2017

Third quarter 2017

(in CHF millions, except EPS)

US GAAP

Non-GAAP 

US GAAP

Non-GAAP

Operating income (loss)

(79)

(71)

(68)

(61)

Net income (loss)

(82)

(73)

(71)

(62)

Basic and diluted EPS

(0.73)

(0.65)

(0.59)

(0.52)

Number of shares (weighted average)

111.8

111.8

119.1

119.1